A5066704375- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Ovarian cancer diagnosis and treatment
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Radiomics and Machine Learning in Medical Imaging
- Peripheral Nerve Disorders
- Gastrointestinal Tumor Research and Treatment
- Colorectal and Anal Carcinomas
- RNA modifications and cancer
- Meningioma and schwannoma management
- Immunodeficiency and Autoimmune Disorders
- Statistical Methods in Clinical Trials
- Drug-Induced Adverse Reactions
- Adrenal and Paraganglionic Tumors
- Multiple Myeloma Research and Treatments
Fiona Stanley Hospital
2017-2025
Amsterdam University Medical Centers
2024
Austin Health
2019-2024
Olivia Newton-John Cancer Wellness & Research Centre
2019-2024
University of Amsterdam
2024
The University of Melbourne
2021-2024
Emma Kinderziekenhuis
2024
Austin Hospital
2020-2021
Sir Charles Gairdner Hospital
2011-2019
Pathwest Laboratory Medicine
2019
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
Abstract In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated phenotype or a non–germinal center (GCB) phenotype, coexpression MYC and BCL2 by immunohistochemistry, cooccurrence BCL6 rearrangements are associated with inferior outcomes. It is unclear whether these variables remain prognostic in stage I/II patients. this retrospective study, we evaluated impact cell origin (COO), as well dual-expressor (DE) status molecular double-hit (DH) status, DLBCL...
Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high FL patients harmonize clinical trial populations. The utilization of GELF (GELFc) in routine therapeutic decision- making poorly described. This multicenter retrospective study evaluated patterns GELFc at presentation decision-making newly diagnosed, advanced-stage...
Tumour 'bulk' has historically been considered an important prognostic marker and clinical tool to guide treatment in patients with lymphoma. However, its use definitions trial designs varies significantly it is unclear how this influenced the relevance of bulk contemporary practice. This comprehensive literature review evaluated definitions, applications impact phase 3 randomised trials four major lymphoma subtypes. Overall, 87 studies were identified across follicular (FL), diffuse large...
Follicular lymphoma (FL) outcomes are heavily influenced by host immune activity with anti-tumor mitigated PD-1/PD-L1 pathway engagement. Combination CD20-directed therapy plus PD-1 inhibition (PD-1i) increases T-cell tumor killing and NK-cell antibody-dependent cell cytotoxicity (ADCC). Mounting evidence supports immune-priming using PD-1i before cancer-directed agents. Our multicentre, open-label, phase II 1st FLOR study (NCT03245021) enrolled 39 previously-untreated advanced-stage FL...
Abstract Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma (RR‐DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial many novel therapies RR‐DLBCL have not been replicated routine care cohorts, as patient populations are heterogeneous eligibility increasingly restrictive. We evaluated outcomes from pola ± patients enrolled a compassionate access...
Summary Primary gastric diffuse large B‐cell lymphoma (PG‐DLBCL) accounts for the majority of extra‐nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort patients with stage I disease, diagnosed between 2006 and 2018, from six centres Australia, Canada Denmark. Our goal was to characterise outcomes, review treatment investigate role interim positron emission tomography (iPET). Thirty‐seven eligible were identified. The median duration follow‐up...
TPS7092 Background: The most common therapy FL pts receive remains chemotherapy which yields high efficacy but also significant toxicity.(Marcus 2017, Rummel 2013). are largely aged over 65 and may require treatment multiple times their disease course thus novel regimens enhance minimise toxicity highly desirable. patient (pt) outcomes influenced by tumor microenvironment composition manipulation with immunotherapy. Ikaros Aiolos, key cell development homeostasis transcription factors...
Summary Grade 3B follicular lymphoma (G3BFL) is a rare thought to sit on continuum between low‐grade FL and diffuse large B‐cell (DLBCL). The prognostic impact of quantitative positron emission tomography (PET) metrics such as total metabolic tumour volume (TMTV), lesion glycolysis (TLG), maximum standard uptake value (SUVmax) have been extensively analysed in DLBCL, but G3BFL data are lacking. Here, we describe PET outcomes radiomic characteristics 46 cases uniformly treated with R‐CHOP...
Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on histological continuum between 'lowgrade' (Grade 1, 2 and 3A FL) diffuse large B-cell (DLBCL) appearing to share features with each. Clinical characteristics outcomes are poorly understood due lack of adequate representation in prospective trials large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, two comparator groups; G3AFL (n=302) DLBCL (n=548). Composite histology or low-grade occurred...
7560 Background: Standard of care immunochemotherapy in front-line (1L) follicular lymphoma (FL) is highly efficacious but not without significant toxicity. High rates grade 3-5 adverse events (AEs), primarily infection and bone marrow suppression, are experienced up to 75% patients. A more tolerable equally effective approach required. PD-1 inhibition, combination with rituximab (R), increases T cell anti-tumour effect & enhances NK antibody dependent cytotoxicity, proven efficacy...